Frank van Engelenburg is an experienced CMC Leader for early and late development of biologics including gene therapy products, monoclonal antibodies, vaccines, and plasma derivatives. As CMC leader he has been involved in multiple clinical trial applications in Europe, US and Japan, regulatory advices on CMC and in marketing authorization applications and biological license applications. With a background in virology (PhD) and molecular biology, he has been leading a viral safety group at Sanquin-NL for more than 10 years. Subsequently he has been a CMC senior and managing consultant for more than 15 years at Kinesis-Pharma (Breda-NL: currently Venn Life Sciences) and Progress Life Sciences (Hoofddorp-NL).
